ATE489379T1 - 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen - Google Patents
2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignenInfo
- Publication number
- ATE489379T1 ATE489379T1 AT04716136T AT04716136T ATE489379T1 AT E489379 T1 ATE489379 T1 AT E489379T1 AT 04716136 T AT04716136 T AT 04716136T AT 04716136 T AT04716136 T AT 04716136T AT E489379 T1 ATE489379 T1 AT E489379T1
- Authority
- AT
- Austria
- Prior art keywords
- perhydrotriazapine
- hyperproliferative
- angiogenic
- oxo
- treatment
- Prior art date
Links
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- 230000002491 angiogenic effect Effects 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 235000013877 carbamide Nutrition 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- -1 diaryl ureas Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45032303P | 2003-02-28 | 2003-02-28 | |
| PCT/US2004/006283 WO2004078746A2 (en) | 2003-02-28 | 2004-03-01 | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE489379T1 true ATE489379T1 (de) | 2010-12-15 |
Family
ID=32962493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04716136T ATE489379T1 (de) | 2003-02-28 | 2004-03-01 | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1599466B1 (de) |
| JP (2) | JP4594925B2 (de) |
| CN (1) | CN1839126A (de) |
| AT (1) | ATE489379T1 (de) |
| CA (1) | CA2516624C (de) |
| DE (1) | DE602004030222D1 (de) |
| ES (1) | ES2357288T3 (de) |
| MX (1) | MXPA05009103A (de) |
| WO (1) | WO2004078746A2 (de) |
| ZA (1) | ZA200506861B (de) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1158985B1 (de) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER |
| ME00275B (me) | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| ATE529406T1 (de) | 2002-02-11 | 2011-11-15 | Bayer Healthcare Llc | Aryl-harnstoffe als kinase inhibitoren |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| WO2004078746A2 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
| EP1636585B2 (de) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl-harnstoffe mit kinasehemmender wirkung |
| EP1663978B1 (de) * | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden |
| AU2013200394B2 (en) * | 2003-07-23 | 2015-07-09 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| EP2295426A1 (de) | 2004-04-30 | 2011-03-16 | Bayer HealthCare, LLC | Substituierte Pyrazolyl-harnstoff-derivate zur Behandlung von Krebs |
| ATE482693T1 (de) | 2005-03-07 | 2010-10-15 | Bayer Schering Pharma Ag | Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs |
| DE102005037499A1 (de) * | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
| WO2007075650A2 (en) | 2005-12-21 | 2007-07-05 | Bayer Healthcare Ag | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders |
| WO2008079629A2 (en) * | 2006-12-21 | 2008-07-03 | Boehringer Ingelheim International Gmbh | Formulations with improved bioavailability |
| CA2675980C (en) * | 2007-01-19 | 2016-06-21 | Bayer Healthcare Llc | Use of dast for treatment of cancers with acquired resistance to kit inhibitors |
| KR100961891B1 (ko) * | 2008-02-01 | 2010-06-09 | 연세대학교 산학협력단 | 혈관신생 억제용 약제학적 조성물 |
| JP2011525503A (ja) * | 2008-06-25 | 2011-09-22 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心不全を処置するためのジアリールウレア |
| JP2012504591A (ja) | 2008-10-02 | 2012-02-23 | レスピバート・リミテツド | ｐ３８ＭＡＰキナーゼ阻害剤 |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| JP5439494B2 (ja) | 2008-10-21 | 2014-03-12 | バイエル ヘルスケア エルエルシー | 肝細胞癌と関連するシグネチャ遺伝子の同定 |
| MX2011006219A (es) | 2008-12-11 | 2011-06-28 | Respivert Ltd | Inhibidores de la proteina cinasa activada por el mitogeno p38. |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| US9556426B2 (en) | 2009-09-16 | 2017-01-31 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
| JP2013516422A (ja) | 2009-12-30 | 2013-05-13 | アビラ セラピューティクス， インコーポレイテッド | タンパク質のリガンド−指向性共有的修飾 |
| CN102617458A (zh) * | 2010-05-18 | 2012-08-01 | 张南 | 抗癌用化合物的制备方法 |
| CN102319242A (zh) * | 2011-10-13 | 2012-01-18 | 济南海乐医药技术开发有限公司 | 吲唑双芳基脲化合物作为蛋白激酶抑制剂的应用 |
| PT3357919T (pt) | 2014-02-14 | 2020-02-20 | Respivert Ltd | Compostos heterocíclicos aromáticos como compostos antiinflamatórios |
| WO2017036405A1 (zh) * | 2015-09-02 | 2017-03-09 | 陈昆锋 | 具有蛋白酪氨酸磷酸酶shp-1激动剂活性的化合物 |
| US10519113B2 (en) * | 2016-08-17 | 2019-12-31 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds, compositions, and methods of treating cancer |
| WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| CN118416236A (zh) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| EP4013412B1 (de) | 2019-08-12 | 2026-01-28 | Deciphera Pharmaceuticals, LLC | Ripretinib zur behandlung gastrointestinaler stromakarzinome |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| EP4084779B1 (de) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Zusammensetzungen von 1-(4-brom-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorphenyl)-3-phenylharnstoff |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| CN115210229A (zh) | 2020-01-03 | 2022-10-18 | 博格有限责任公司 | 多环酰胺作为治疗癌症的ube2k调节剂 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| WO2025253311A1 (en) | 2024-06-04 | 2025-12-11 | Hetero Labs Limited | 1,2-dicarboxamide compounds as kinase inhibitors |
| WO2026074526A1 (en) | 2024-10-04 | 2026-04-09 | Hetero Labs Limited | 1,2-dicarboxamide compounds as kinase inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69831013T2 (de) * | 1997-12-22 | 2006-04-20 | Bayer Pharmaceuticals Corp., West Haven | Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen |
| EP1140840B1 (de) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren |
| US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| JP2001106673A (ja) * | 1999-07-26 | 2001-04-17 | Banyu Pharmaceut Co Ltd | ビアリールウレア誘導体 |
| EP1232150B1 (de) * | 1999-11-16 | 2007-10-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Harnstoff derivate als entzündungshemmende mittel |
| KR20020084116A (ko) * | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
| WO2004078746A2 (en) * | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
-
2004
- 2004-03-01 WO PCT/US2004/006283 patent/WO2004078746A2/en not_active Ceased
- 2004-03-01 AT AT04716136T patent/ATE489379T1/de not_active IP Right Cessation
- 2004-03-01 CA CA2516624A patent/CA2516624C/en not_active Expired - Fee Related
- 2004-03-01 DE DE602004030222T patent/DE602004030222D1/de not_active Expired - Lifetime
- 2004-03-01 CN CNA2004800115476A patent/CN1839126A/zh active Pending
- 2004-03-01 JP JP2006501213A patent/JP4594925B2/ja not_active Expired - Fee Related
- 2004-03-01 ES ES04716136T patent/ES2357288T3/es not_active Expired - Lifetime
- 2004-03-01 EP EP04716136A patent/EP1599466B1/de not_active Expired - Lifetime
- 2004-03-01 MX MXPA05009103A patent/MXPA05009103A/es unknown
-
2005
- 2005-08-26 ZA ZA200506861A patent/ZA200506861B/en unknown
-
2010
- 2010-05-27 JP JP2010122149A patent/JP2010229142A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2516624A1 (en) | 2004-09-16 |
| JP2006519182A (ja) | 2006-08-24 |
| JP4594925B2 (ja) | 2010-12-08 |
| JP2010229142A (ja) | 2010-10-14 |
| WO2004078746A3 (en) | 2004-12-02 |
| EP1599466B1 (de) | 2010-11-24 |
| CN1839126A (zh) | 2006-09-27 |
| ZA200506861B (en) | 2006-06-28 |
| ES2357288T3 (es) | 2011-04-25 |
| WO2004078746A2 (en) | 2004-09-16 |
| DE602004030222D1 (de) | 2011-01-05 |
| CA2516624C (en) | 2013-05-14 |
| EP1599466A2 (de) | 2005-11-30 |
| MXPA05009103A (es) | 2006-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE489379T1 (de) | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen | |
| WO2004078747A8 (en) | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | |
| MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| ATE556713T1 (de) | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer | |
| EA200900733A1 (ru) | ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ | |
| ATE365720T1 (de) | Agonisten von beta-adrenorezeptoren | |
| TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| ATE453636T1 (de) | Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren | |
| SE0102764D0 (sv) | Compounds | |
| CY1109422T1 (el) | Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| UA92503C2 (ru) | Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств | |
| EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
| ATE396973T1 (de) | Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit | |
| EP1689713A4 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
| WO2004078748A3 (en) | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | |
| TR200101978T2 (tr) | 3,3-Biarilpiperidin ve 2,2-biarilmorfolin türevleri. | |
| ATE267816T1 (de) | Tan-1057 derivate | |
| DE602004021363D1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
| CA2534634A1 (en) | Azolidinecarbonitriles and their use as dpp-iv inhibitors | |
| DE60108130D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten | |
| MY146802A (en) | Novel drugs for treating respiratory diseases | |
| DE69829861D1 (de) | 2-aminopyridine als inhibitoren von cyclooxygenase-2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |